correlation between CD200 expression and oxidant-antioxidant status in newly diagnosed B-chronic lymphocytic leukemia patients

Abstract

B cell chronic lymphocytic leukemia (B-CLL) is the highest incidence of lymphoproliferative malignant disease in most adults in the western world. Due to the importance of the pathogenicity and risk factors of this disease, this study was designed to analyze the expression the pattern of CD200 by flow cytometer immunophenotyping (FCI) and the association between this marker and some clinical features and oxidant-antioxidant status in B-chronic lymphocytic leukemia patients. This study was conducted on 60 newly diagnostic patients with B-CLL and 30 apparently healthy individuals as control group. The socio-demographic information including (age and sex) and clinical data were also collected in period 20 February 2021 to 25 December. The result of statistical analysis of the present study showed that out of the 60 patients, 39 were male and 21 females, with 30 controls (12 males and 18 females). The mean age of adults patients was (64.04 ± 5.6) years, and the adults control mean age of (63.33 ± 4.70) years therefore, there was a higher prevalence p value ≤0.05 of newly diagnosed CLL patients in males (65.0 %) in compared with females (35.0 %).

Risk factors for iron metabolic disorders in newly diagnosed B-chronic lymphocytic leukemia patients

“…OS in B-CLL is concurrently produced by increased ROS production, related mostly to the mitochondrial activity of B-CLL cells, and insufficient antioxidant defences. [32,33]. The decreased antioxidant capacity found in the sera of our B-CLL patients may be related to a consumption of antioxidants and/or to a reduced efficacy of antioxidant defences due to the systemic excess of ROS that is common in cancer [34].Accumulating evidence by two important studies suggested that increased OS and the relative deficiency of the antioxidant defence system are involved in crucial steps of B-CLL development [28,35].…”